Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth - GBI Research Reports

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth - GBI Research Reports
Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
Published Aug 01, 2016
176 pages — Published Aug 01, 2016
Price US$ 4,995.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 90-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Scope

The current South-East Asia T2DM market contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.
- What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 49%, with the overall attrition rate for T2DM standing at 75%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2015-2022 forecast period, the South-East Asia T2DM therapeutics market is expected to increase in value at a CAGR of 7.1%, from $1.7 billion to over $2.7 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy

This report will enable you to -
- Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.&

  
Source:
Document ID
GBIHC421MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents46
  1.1 List of Tables71
  1.2 List of Figures73
2 Introduction1033
  2.1 Disease Introduction101
  2.2 Epidemiology101
  2.3 Symptoms111
  2.4 Etiology and Pathophysiology113
  2.5 Diagnosis141
  2.6 Classification151
  2.7 Prognosis151
  2.8 Treatment Options161
    2.8.1 Treatment Algorithm162
    2.8.2 Non-insulin T2DM Therapies181
      2.8.2.1 Biguanides181
      2.8.2.2 Sulfonylureas and Meglitinides181
      2.8.2.3 Thiazolidinediones191
      2.8.2.4 Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors191
      2.8.2.5 Sodium Glucose Linked Transporter-2 (SGLT-2) Inhibitors201
      2.8.2.6 Other Non-insulin Therapies211
         211
        2.8.2.6.2 Bile Acid Sequestrants211
    2.8.3 Insulin T2DM Therapies211
  2.9 Treatment Segments221
    2.9.1 Non-insulin therapies231
      2.9.1.1 Metformin monotherapy versus placebo231
      2.9.1.2 Immediate-Release Metformin versus Extended-Release Metformin either as Monotherapies or in Combination with Other Oral Antidiabetic Agents241
      2.9.1.3 Metformin Monotherapy versus Glyburide Monotherapy versus Metformin in Combination with Glyburide252
      2.9.1.4 Actos (pioglitazone) versus Placebo as Monotherapy271
      2.9.1.5 Byetta (exenatide) versus Bydureon (exenatide) either as Monotherapies or in Combination with Oral Antidiabetic Drugs282
      2.9.1.6 Victoza (liraglutide) versus Tanzeum (albiglutide) in Combination with Oral Antidiabetic Drugs301
      2.9.1.7 Trulicity (dulaglutide) versus Victoza (liraglutide) in Combination with Metformin311
      2.9.1.8 Januvia (sitagliptin) versus Glipizide as Add-On Therapy to Metformin321
      2.9.1.9 Galvus (vildagliptin) versus Actos (pioglitazone) as Add-On Therapy to Metformin331
      2.9.1.10 Onglyza (saxagliptin) versus Forxiga (dapagliflozin) versus Onglyza in Combination with Forxiga as Add-On Therapies to Metformin341
      2.9.1.11 Jardiance (empagliflozin), Trajenta (linagliptin) and Glyxambi (empagliflozin and linagliptin) as Monotherapies or as Add-On Therapies to Metformin352
      2.9.1.12 Invokana (canagliflozin) versus Glimepiride as Add-On Therapy to Metformin371
    2.9.2 Insulin Therapies381
      2.9.2.1 Lantus (insulin glargine) versus Levemir (insulin detemir) as Add-On Therapy to Glucose-Lowering Drugs381
      2.9.2.2 Lantus (insulin glargine) versus Toujeo (insulin glargine) as Add-On Therapies to Oral Antidiabetic Drugs or Meal-Time Insulin382
      2.9.2.3 Tresiba (insulin degludec) versus Lantus (insulin glargine) as Add-On Therapy to Oral Antidiabetic Drugs401
  2.10 Co-morbidities and Complications412
3 Marketed Products4329
  3.1 Overview431
  3.2 Biguanides441
    3.2.1 Metformin441
  3.3 Sulfonylureas451
  3.4 Thiazolidinediones461
    3.4.1 Pioglitazone462
    3.4.2 Duvie (lobeglitazone) Chong Kun Dang481
  3.5 GLP-1 Receptor Agonists481
    3.5.1 Byetta (exenatide) Eli Lilly481
    3.5.2 Bydureon (exenatide) AstraZeneca491
    3.5.3 Victoza (liraglutide) Novo Nordisk502
    3.5.4 Lyxumia (lixisenatide) Sanofi521
    3.5.5 Tanzeum (albiglutide) GlaxoSmithKline531
  3.6 DPP-4 Inhibitors541
    3.6.1 Januvia (sitagliptin) Merck541
    3.6.2 Galvus (vildagliptin) Novartis552
    3.6.3 Onglyza (saxagliptin) Bristol-Myers Squibb/AstraZeneca571
    3.6.4 Trajenta (linagliptin) Bristol-Myers Squibb/AstraZeneca581
    3.6.5 Zemiglo (gemigliptin) LG Life Sciences591
    3.6.6 Suganon (evogliptin) Dong-A ST591
    3.6.7 Gadret (anagliptin) JW Pharmaceutical601
    3.6.8 Nesina (alogliptin) Takeda611
    3.6.9 Tenelia (teneligliptin) Mitsubishi Tanabe Pharma611
  3.7 SGLT-2 Inhibitors621
    3.7.1 Forxiga (dapagliflozin) AstraZeneca621
    3.7.2 Invokana (canagliflozin) Janssen631
    3.7.3 Jardiance (empagliflozin) Boehringer Ingelheim641
    3.7.4 Suglat (ipragliflozin) Astellas651
  3.8 Insulin Therapies661
    3.8.1 Lantus (insulin glargine) Sanofi661
    3.8.2 Levemir (insulin detemir) Novo Nordisk671
    3.8.3 Tresiba (insulin degludec) Novo Nordisk671
    3.8.4 Toujeo (insulin glargine) Sanofi681
  3.9 Comparative Efficacy and Safety of Marketed Products693
4 Pipeline7220
  4.1 Overview721
  4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type731
  4.3 Pipeline by Molecular Target744
  4.4 Promising Pipeline Candidates781
    4.4.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) Novo Nordisk782
      4.4.1.1 Forecast801
    4.4.2 Trulicity (dulaglutide)812
      4.4.2.1 Forecast831
    4.4.3 Ertugliflozin Pfizer831
      4.4.3.1 Forecast841
    4.4.4 Bexagliflozin Theracos841
      4.4.4.1 Forecast851
    4.4.5 Omarigliptin Merck861
      4.4.5.1 Forecast871
  4.5 Comparative Efficacy and Safety of Pipeline Products881
  4.6 Product Competitive Framework884
5 Clinical Trial Analysis9210
  5.1 Failure Rate921
    5.1.1 Overall Failure Rate921
    5.1.2 Failure Rate by Phase and Molecule Type921
    5.1.3 Failure Rate by Phase and Molecular Target931
  5.2 Clinical Trial Size944
  5.3 Clinical Trial Duration981
    5.3.1 Trial Duration by Stage of Development and Molecule Type982
    5.3.2 Trial Duration by Stage of Development and Molecular Target1001
  5.4 Summary of Clinical Trial Metrics1002
6 Multi-Scenario Forecast10221
  6.1 Geographical Markets1021
  6.2 South-East Asia Markets1023
  6.3 South Korea1051
    6.3.1 Treatment Usage Patterns1051
    6.3.2 Annual Cost of Therapy1051
    6.3.3 Market Size1061
  6.4 Singapore1071
    6.4.1 Treatment Usage Patterns1071
    6.4.2 Annual Cost of Therapy1071
    6.4.3 Market Size1081
  6.5 Taiwan1091
    6.5.1 Treatment Usage Patterns1091
    6.5.2 Annual Cost of Therapy1091
    6.5.3 Market Size1101
  6.6 Malaysia1111
    6.6.1 Treatment Usage Patterns1111
    6.6.2 Annual Cost of Therapy1121
    6.6.3 Market Size1131
  6.7 Philippines1131
    6.7.1 Treatment Usage Patterns1131
    6.7.2 Annual Cost of Therapy1141
    6.7.3 Market Size1151
  6.8 Thailand1151
    6.8.1 Treatment Usage Patterns1151
    6.8.2 Annual Cost of Therapy1161
    6.8.3 Market Size1171
  6.9 Vietnam1181
    6.9.1 Treatment Usage Patterns1181
    6.9.2 Annual Cost of Therapy1181
    6.9.3 Market Size1191
  6.10 Indonesia1201
    6.10.1 Treatment Usage Patterns1201
    6.10.2 Annual Cost of Therapy1211
    6.10.3 Market Size1221
7 Market Dynamics, (Drivers and Barriers)1232
  7.1 Drivers1231
    7.1.1 Aging Population, Increasing Obesity and Growing Economy1231
    7.1.2 Increasing Awareness of T2DM1231
    7.1.3 Continued Uptake of Recently Approved Drug Classes1231
    7.1.4 Promising Late-Stage Pipeline Products can Change the Treatment Paradigm1231
    7.1.5 Enhanced Usage of Combination Therapies1231
  7.2 Barriers1241
    7.2.1 Non-pharmacological First-line Treatment1241
    7.2.2 Widespread Usage of Generic Drugs1241
    7.2.3 Poor Adherence to Treatment Regimens1241
    7.2.4 Generic Erosion Resulting from Patent Expirations1241
8 Deals and Strategic Consolidations12513
  8.1 Licensing Deals1251
    8.1.1 Deals by Region and Value1251
    8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value1261
    8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target1272
    8.1.4 Key Licensing Deals1291
      8.1.4.1 Emisphere Signs New Licensing Agreement with Novo Nordisk to Develop Oral Formulations Targeting Metabolic Indications1291
      8.1.4.2 Amunix Announces Exclusive Agreements with Naia to Develop GLP-1 and GLP-2 XTEN Products1301
      8.1.4.3 Eli Lilly Enters into Licensing Agreement with Adocia1301
  8.2 Co-development Deals1301
    8.2.1 Deals by Region and Value1302
    8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value1322
    8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target1342
    8.2.4 Key Co-Development Deals1361
      8.2.4.1 Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 6501361
      8.2.4.2 Merck Enters into Co-Development Agreement with Pfizer for ertugliflozin1371
      8.2.4.3 AstraZeneca Enters into Research Agreement with Inserm1371
      8.2.4.4 Intarcia Therapeutics Enters into Co-Development Agreement with Numab1371
      8.2.4.5 AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb1371
9 Appendix13839
  9.1 All Pipeline Drugs by Phase of Development13817
    9.1.1 Discovery1383
    9.1.2 Preclinical1418
    9.1.3 IND/CTA-filed1491
    9.1.4 Phase I1492
    9.1.5 Phase II1512
    9.1.6 Phase III1531
    9.1.7 Pre-registration1541
  9.2 Market Forecasts to 20221555
    9.2.1 South-East Asia1551
    9.2.2 South Korea1551
    9.2.3 Singapore1561
    9.2.4 Taiwan1561
    9.2.5 Malaysia1571
    9.2.6 Philippines1571
    9.2.7 Thailand1581
    9.2.8 Vietnam1581
    9.2.9 Indonesia1591
  9.3 References15911
  9.4 Abbreviations1702
  9.5 Research Methodology1724
    9.5.1 Secondary Research1721
    9.5.2 Marketed Product Profiles1731
    9.5.3 Late-Stage Pipeline Candidates1731
    9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products1731
    9.5.5 Pipeline Analysis1731
      9.5.5.1 Overall Pipeline1731
      9.5.5.2 Clinical Trials1741
        9.5.5.2.1 Failure Rate1741
        9.5.5.2.2 Clinical Trial Size1741
        9.5.5.2.3 Clinical Trial Duration1741
        9.5.5.2.4 Clinical Trial Endpoint Analysis1741
    9.5.6 Forecasting Model1741
    9.5.7 Deals Data Analysis1751
  9.6 Contact Us1761
  9.7 Disclaimer1761

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" Aug 01, 2016. Alacra Store. Mar 29, 2024. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Type-2-Diabetes-Mellitus-Therapeutics-in-South-East-Asia-Markets-to-2022-Increasing-Usage-of-Newer-Therapies-and-Expanding-Treatment-Population-to-Encourage-Robust-Growth-2115-733>
  
APA:
GBI Research Reports. (2016). Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth Aug 01, 2016. New York, NY: Alacra Store. Retrieved Mar 29, 2024 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Type-2-Diabetes-Mellitus-Therapeutics-in-South-East-Asia-Markets-to-2022-Increasing-Usage-of-Newer-Therapies-and-Expanding-Treatment-Population-to-Encourage-Robust-Growth-2115-733>
  
US$ 4,995.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.